Back to top
more

Calliditas Therapeutics (CALT)

(Delayed Data from NSDQ)

$40.88 USD

40.88
34,106

+0.53 (1.31%)

Updated Aug 27, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CALT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Calliditas Therapeutics AB Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 92 124 111 109 80
Receivables 17 8 0 0 5
Notes Receivable 0 0 0 0 0
Inventories 2 0 0 0 0
Other Current Assets 9 8 7 4 2
Total Current Assets 120 140 118 113 87
Net Property & Equipment 2 1 1 0 0
Investments & Advances 2 1 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2 1 0 0 0
Intangibles 45 48 47 50 2
Deposits & Other Assets 0 0 0 0 0
Total Assets 175 194 170 164 89
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 9 16 8 6 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 26 14 6 5 3
Income Taxes Payable 1 1 0 0 0
Other Current Liabilities 2 2 1 1 0
Total Current Liabilities 38 32 16 12 6
Mortgages 0 0 0 0 0
Deferred Taxes/Income 4 4 4 9 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 89 71 22 0 0
Non-Current Capital Leases 3 2 3 0 0
Other Non-Current Liabilities 10 9 8 7 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 144 118 53 27 6
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 249 257 287 233 135
Retained Earnings -217 -182 -166 -100 -52
Other Equity 0 1 -3 4 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 32 76 118 137 83
Total Liabilities & Shareholder's Equity 175 194 170 164 89
Total Common Equity 32 76 118 137 83
Shares Outstanding 29.70 29.70 26.10 23.90 NA
Book Value Per Share 1.06 2.56 4.50 5.73 0.00

Fiscal Year End for Calliditas Therapeutics AB Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 74 78 92 73 82
Receivables 21 18 17 12 14
Notes Receivable 0 0 0 0 0
Inventories 4 3 2 1 2
Other Current Assets 9 7 9 9 8
Total Current Assets 108 106 120 96 106
Net Property & Equipment 2 2 2 1 1
Investments & Advances 3 2 2 2 2
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 3 3 2 2 2
Intangibles 44 45 45 44 49
Deposits & Other Assets 0 0 0 0 0
Total Assets 163 162 175 149 162
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 14 10 9 6 7
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 24 26 26 23 18
Income Taxes Payable 0 0 1 0 0
Other Current Liabilities 2 3 2 2 3
Total Current Liabilities 40 39 38 32 28
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 3 4 4 4
Convertible Debt 0 0 0 0 0
Long-Term Debt 92 95 89 69 72
Non-Current Capital Leases 2 3 3 3 2
Other Non-Current Liabilities 15 10 10 9
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 153 151 144 117 114
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 0 0 249 0 0
Retained Earnings 0 0 -217 0 0
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 10 12 32 33 48
Total Liabilities & Shareholder's Equity 163 162 175 149 162
Total Common Equity 10 12 32 33 48
Shares Outstanding 29.70 29.70 29.70 29.70 29.70
Book Value Per Share 0.34 0.39 1.06 1.10 1.61